Oorsprong van het eerstegraads netwerk van Daniel Feig
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
XORTX Pharma Corp.
 XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Daniel Feig via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| CORREVIO PHARMA CORP. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| TRILLIUM THERAPEUTICS | Biotechnology | Founder | |
| Clarkson University | College/University | Masters Business Admin | |
BMO Capital Partners
 BMO Capital Partners Investment ManagersFinance BMO Capital Partners (BMO Capital) is a private equity subsidiary of BMO Equity Partners Inc. founded in 1996. The firm is headquartered in Toronto, Canada. | Investment Managers | Director/Board Member | |
| University of Calgary | College/University | Doctorate Degree | |
| MANY BRIGHT IDEAS TECHNOLOGIES INC. | Medical/Nursing Services | Comptroller/Controller/Auditor | |
Veracyte SD, Inc.
 Veracyte SD, Inc. Miscellaneous Commercial ServicesCommercial Services Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company?s differentiated approach measures the biological activity of a patient?s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient?s tumor, enabling physicians to select an optimal therapy. The firm?s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director of Finance/CFO | |
| Aspreva Pharmaceuticals SA | President | ||
| XORTX THERAPEUTICS INC. | Pharmaceuticals: Major | Founder Director of Finance/CFO |
Statistieken
Internationaal
| Canada | 9 |
| Verenigde Staten | 4 |
| Zwitserland | 2 |
Sectoraal
| Health Technology | 7 |
| Consumer Services | 3 |
| Finance | 2 |
| Health Services | 2 |
| Commercial Services | 2 |
Operationeel
| Director of Finance/CFO | 6 |
| President | 3 |
| Director/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
Sterkste connecties
| Insiders | |
|---|---|
| David G. Matthews | 10 |
| Allen Davidoff | 5 |
| Henk ter Keurs | 1 |
- Beurs
- Insiders
- Daniel Feig
- Bedrijfsconnecties
